Lorabid Side Effects

Generic Name: loracarbef

Note: This page contains information about the side effects of loracarbef. Some of the dosage forms included on this document may not apply to the brand name Lorabid.

Not all side effects for Lorabid may be reported. You should always consult a doctor or healthcare professional for medical advice. Side effects can be reported to the FDA here.

For the Consumer

Applies to loracarbef: oral capsule, oral powder for suspension

In addition to its needed effects, some unwanted effects may be caused by loracarbef (the active ingredient contained in Lorabid). In the event that any of these side effects do occur, they may require medical attention.

If any of the following side effects occur while taking loracarbef, check with your doctor or nurse as soon as possible:

More common
  • Itching
  • skin rash

Some of the side effects that can occur with loracarbef may not need medical attention. As your body adjusts to the medicine during treatment these side effects may go away. Your health care professional may also be able to tell you about ways to reduce or prevent some of these side effects. If any of the following side effects continue, are bothersome or if you have any questions about them, check with your health care professional:

More common
  • Diarrhea
  • loss of appetite
  • nausea and vomiting
  • stomach pain
Rare
  • Dizziness
  • drowsiness
  • headache
  • itching or discharge from the vagina
  • nervousness
  • trouble in sleeping

For Healthcare Professionals

Applies to loracarbef: oral capsule, oral powder for reconstitution

General

Loracarbef (the active ingredient contained in Lorabid) is generally well tolerated.[Ref]

Gastrointestinal

Gastrointestinal side effects have included diarrhea (4.1%), nausea (1.9%), vomiting (1.4%), abdominal pain (1.4%), and anorexia. The incidence of side effects increases with higher doses. Pseudomembranous colitis has been reported in patients treated with beta-lactam antibiotics.[Ref]

Nervous system

Nervous system side effects have included headache (2.9%), somnolence, insomnia, and dizziness. Some beta-lactam antibiotics have been associated with seizures in renally impaired patients.[Ref]

Hypersensitivity

Hypersensitivity reactions have included rash (1.2%), urticaria, pruritus, and erythema multiforme. Anaphylaxis, serum-sickness-like reactions, and Stevens-Johnson syndrome have been reported rarely. Beta-lactam antibiotics have been associated with toxic epidermal necrolysis,[Ref]

Respiratory

Respiratory side effects have included rhinitis (1.6%).[Ref]

Hematologic

Hematologic side effects have included transient thrombocytopenia, leukopenia, and eosinophilia. Beta-lactam antibiotics as a class have been associated with agranulocytosis, aplastic anemia, hemolytic anemia, hemorrhage, positive direct Coombs' test, pancytopenia, neutropenia, and prolonged prothrombin time.[Ref]

Renal

Renal side effects have included transient elevations in serum creatinine and BUN. Some beta-lactam antibiotics have been associated with toxic nephropathy.[Ref]

Hepatic

Hepatic side effects have included transient elevations in AST (SGOT), ALT (SGPT), and alkaline phosphatase. Hepatic dysfunction including cholestasis with or without jaundice has been rarely reported. Some beta-lactam antibiotics have been associated with LDH elevations.[Ref]

A 73-year-old man developed itching and jaundice, pale stools, and right upper quadrant pain two weeks after completion of a four week course of loracarbef for pneumonia. Bilirubin, AST, ALT, alkaline phosphatase levels were elevated. Liver biopsy showed widening of portal areas, pericellular fibrosis, and irregular fibrous bands in the parenchyma. Swollen hepatocytes and cholestasis in the cytoplasma and canaliculi were observed. Lab values returned to normal after 10 weeks.[Ref]

Cardiovascular

Cardiovascular side effects have included vasodilatation.[Ref]

Genitourinary

Genitourinary side effects have included vaginitis (1.3%) and vaginal moniliasis (1.1%).[Ref]

References

1. Therasse DG "The safety profile of loracarbef: clinical trials in respiratory, skin, and urinary tract infections." Am J Med 92 (1992): s20-5

2. Brogden RN, McTavish D "Loracarbef. A review of its antimicrobial activity, pharmacokinetic properties and therapeutic efficacy." Drugs 45 (1993): 716-36

3. "Product Information. Lorabid (loracarbef)." Lilly, Eli and Company, Indianapolis, IN.

4. Bjornsson E, Olsson R "Acute liver injury due to loracarbef." J Hepatol 26 (1997): 739-40

Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate safety, effectiveness, or appropriateness for any given patient. Drugs.com does not assume any responsibility for any aspect of healthcare administered with the aid of materials provided. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the substances you are taking, check with your doctor, nurse, or pharmacist.

Hide
(web2)